Literature DB >> 14739629

Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage.

Johanna H H van Geest-Daalderop1, Barbara A Hutten, Augueste Sturk, Marcel M Levi.   

Abstract

BACKGROUND: This retrospective study was performed to develop a model to predict the maintenance dosage of the vitamin K antagonist acenocoumarol, based upon the first INR after a standard initial dosage regimen.
MATERIAL AND METHODS: Outpatients with atrial fibrillation ( n = 284) and initial regimens of 6-4 or 6-4-2 mg acenocoumarol on day 1, 2 and 3, respectively, were included. The maintenance dosage of the period 3-6 months after the installment was related to the first INR after those standard initial dosage regimens, because in that period the INR was 76% of the time within the therapeutic range and therefore considered suitable to perform the analysis.
RESULTS: A clear relation was found between the first INR, the maintenance dosage and the age. A model that predicts the maintenance dosage immediately after the standard initial dosage and based on the first INR and adjusted for age, has been developed, according to the formula: required dosage = 5.03-1.65 * ln (first INR) - 0.01 * age.
CONCLUSION: We have developed a formula to predict the maintenance dosage of acenocoumarol. With this formula it is possible to install this maintenance dosage and thus achieve oral anticoagulant therapy within the therapeutic range at an earlier stage. This will have to be shown in a prospective study.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14739629     DOI: 10.1023/B:THRO.0000011375.12034.62

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  21 in total

1.  The association of age with dosage requirement for warfarin.

Authors:  M Redwood; C Taylor; B J Bain; J H Matthews
Journal:  Age Ageing       Date:  1991-05       Impact factor: 10.668

2.  Aging and the anticoagulant response to warfarin therapy.

Authors:  J H Gurwitz; J Avorn; D Ross-Degnan; I Choodnovskiy; J Ansell
Journal:  Ann Intern Med       Date:  1992-06-01       Impact factor: 25.391

3.  Flexible induction dose regimen for warfarin and prediction of maintenance dose.

Authors:  A Fennerty; J Dolben; P Thomas; G Backhouse; D P Bentley; I A Campbell; P A Routledge
Journal:  Br Med J (Clin Res Ed)       Date:  1984-04-28

4.  A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients.

Authors:  J Gedge; S Orme; K K Hampton; K S Channer; T J Hendra
Journal:  Age Ageing       Date:  2000-01       Impact factor: 10.668

5.  A new regimen for starting warfarin therapy in out-patients.

Authors:  A Oates; P R Jackson; C A Austin; K S Channer
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

6.  Factors affecting the maintenance dose of warfarin.

Authors:  A H James; R P Britt; C L Raskino; S G Thompson
Journal:  J Clin Pathol       Date:  1992-08       Impact factor: 3.411

7.  A method to determine the optimal intensity of oral anticoagulant therapy.

Authors:  F R Rosendaal; S C Cannegieter; F J van der Meer; E Briët
Journal:  Thromb Haemost       Date:  1993-03-01       Impact factor: 5.249

8.  Assessment of therapeutic quality control in a long-term anticoagulant trial in post-myocardial infarction patients.

Authors:  A J Azar; J W Deckers; F R Rosendaal; P F van Bergen; F J van der Meer; J J Jonker; E Briët
Journal:  Thromb Haemost       Date:  1994-09       Impact factor: 5.249

9.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Authors:  M M Koopman; P Prandoni; F Piovella; P A Ockelford; D P Brandjes; J van der Meer; A S Gallus; G Simonneau; C H Chesterman; M H Prins
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

10.  A warfarin induction regimen for out-patient anticoagulation in patients with atrial fibrillation.

Authors:  R C Tait; A Sefcick
Journal:  Br J Haematol       Date:  1998-06       Impact factor: 6.998

View more
  2 in total

1.  Improvement in the regulation of the vitamin K antagonist acenocoumarol after a standard initial dose regimen: prospective validation of a prescription model.

Authors:  Johanna H H Van Geest-Daalderop; Barbara A Hutten; Nathalie C V Péquériaux; Marcel Levi; Augueste Sturk
Journal:  J Thromb Thrombolysis       Date:  2008-02-13       Impact factor: 2.300

Review 2.  Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review.

Authors:  Elizabeth S Mearns; Jessica Hawthorne; Ju-Sung Song; Craig I Coleman
Journal:  BMJ Open       Date:  2014-06-20       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.